Science-driven approach powering a pipeline of next-generation, combination and pan-cancer therapies for patients globally
Apollomics is an innovative biotechnology company focusing on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer.
We are thrilled to announce that Jane Wang, PhD has joined us as CSO, and will also serve as our GM in China. We look forward to her contributions to grow our global team to discover and advance new compounds into the clinic. #oncology #ClinicalResearch
Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer - Apollomics, Inc.
Foster City, CA, and Hangzhou, China, July 26, 2022 — Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and develop...
bit.ly
Thank you to the @NFCR for allowing us to highlight the importance of #PrescisionMedicine as a method to treat certain cancers. #oncology
A quick reminder that we are hosting a corporate update call this week! Register here: . #oncology #investorday
Events & Presentations - Apollomics, Inc.
...
bit.ly
To start the year, we will be presenting a corporate update on January 26th (U.S.) and January 27th (Asia). Please join us! #Oncology #investorday
Apollomics Inc. To Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022 - Apollomics, Inc.
English and Chinese Sessions to be Held to Accommodate Multiple Time Zones Foster City, CA, Shanghai and Hangzhou, China, January 12, 2021 — Apollo...
bit.ly
Congratulations to our #CEO Guo-Liang Yu who has been appointed as Chairman of the Board for The BayHelix Group!
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group - Apollomics, Inc.
Foster City, CA, and Hangzhou, China, January 04, 2022 — Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and de...
bit.ly
We are thrilled to announce we have entered late-stage development with the initiation of our Phase 3 #clinicaltrial with APL-106 in Chinese patients with R/R Acute Myeloid Leukemia #oncology
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia - Apollomics, Inc.
Foster City, CA, Shanghai and Hangzhou, China, November 22, 2021 — Apollomics Inc., an innovative biopharmaceutical company committed to the discov...
bit.ly
With our partners @Edison Oncology, we are pleased to announce we have treated our first patient with APL-122 in a Phase I/IIa #clinicaltrial. This first-in-human study is in patients with advanced stage ErbB-positive cancers in solid tumors. #oncology
Edison Oncology and Apollomics Inc. Announce Treatment of First Patient For EO1001 (APL-122) in a Phase I/IIa Clinical Trial - Apollomics, Inc.
MENLO PARK, Calif., FOSTER CITY, Calif. and HANGZHOU, China, September 30, 2021 – Edison Oncology Holding Corp. (“Edison Oncology”), a c...
bit.ly
We were honored to join the @GO2Foundation run/walk hybrid event last weekend to raise money for #lungcancer awareness and spread the word about our #SPARTA clinical trial.
